Dublin-based biopharma company has cash position of $60.9m
Group plots dual Nasdaq listing to create enlarged rare disease company
Firms estimates new deal will increase number of patients for treatment by 25%
YOU MAY ALSO LIKE...
Crosswords & puzzles to keep you challenged and entertained
Follow all the action from this year's championship
Start The Search For Your Next Job
Latest news and analysis on the battle to save the planet
A project examining attitudes about the future of Ireland
Weddings, Births, Deaths and other family notices